| Grant number: | 15/10436-6 |
| Support Opportunities: | Scholarships in Brazil - Doctorate (Direct) |
| Start date: | October 01, 2015 |
| End date: | February 28, 2019 |
| Field of knowledge: | Biological Sciences - Microbiology - Applied Microbiology |
| Principal Investigator: | Lucio Holanda Gondim de Freitas Junior |
| Grantee: | Thalita Camelo da Silva Ferreira |
| Host Institution: | Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil |
Abstract Leishmaniasis is a set of clinical manifestations caused by protozoa of the genus Leishmania. With an estimated 12 million people infected, it is a public health problem, being considered one of the ten priority global epidemics. However, it has not an effective treatment, safe, easily manageable and economically viable. All drugs in use or advanced clinical stage have limitations such as toxicity, long treatment periods and high costs. Furthermore, it has been reported the development of resistance to many of these drugs. Consequently, the development of a new antileishmanial drug with better efficacy and safety is a medical need. Phenotypic screening assays show promising in the identification of compounds antileishmaniasis. However, there is much to optimize in the HCS platforms. The central objective of the project is to standardize testing for screening drugs against Leishmania sp. by HCS, thereby establishing a pipeline with robustness, high sensitivity, low variability and reliability, which will enable the screening of thousands of compounds continuously. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |